Abingdon Health (LON:ABDX) Reaches New 1-Year High – Should You Buy?

Abingdon Health Plc (LON:ABDX)’s stock price hit a new 52-week high during trading on Wednesday . The company traded as high as GBX 13 and last traded at GBX 12, with a volume of 4769792 shares traded. The stock had previously closed at GBX 11.75.

Abingdon Health Price Performance

The firm’s 50 day simple moving average is GBX 8.17 and its two-hundred day simple moving average is GBX 7.11. The company has a debt-to-equity ratio of 15.05, a current ratio of 1.91 and a quick ratio of 1.96. The firm has a market capitalization of £30.13 million, a P/E ratio of -14.81 and a beta of 0.12.

Abingdon Health (LON:ABDX) last announced its quarterly earnings data on Tuesday, March 17th. The company reported GBX (0.43) earnings per share (EPS) for the quarter. Abingdon Health had a negative net margin of 33.88% and a negative return on equity of 55.91%.

Abingdon Health Company Profile

Abingdon Health is a world leading contract developer and manufacturer (CDMO) of high-quality rapid tests across all industry sectors, including healthcare, infectious disease, animal health, environmental and self-testing. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and regulatory approval. The Company also markets its own range of self-tests under the Abingdon Simply Test brand (www.abingdonsimplytest.com) and has developed and marketed its own labelled tests.